Integrated BioPharma (INBP) 10-Q 5 Nov 15 2016 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2015	Nov. 05, 2015
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Entity Central Index Key	1,016,504
Trading Symbol	inbp
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		21,105,174
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Sales, net	$ 9,445	$ 8,582
Cost of sales	8,130	7,281
Gross profit	1,315	1,301
Selling and administrative expenses	830	852
Operating income	485	449
Other income (expense), net:
Interest expense	(237)	(240)
Change in fair value of derivative liabilities	(3)	214
Other income, net	24	9
Other expense, net	(216)	(17)
Income before income taxes	269	432
Income tax expense, net	28	29
Net income	$ 241	403
Interest expense on Convertible debt - CD Financial, LLC		82
Accretion of Convertible debt - CD Financial, LLC		28
Change in fair value of derivative liabilities		(214)
Diluted net income	$ 241	$ 299
Basic net income per common share (in dollars per share)	$ 0.01	$ 0.02
Diluted net income per common share (in dollars per share)	$ 0.01	$ 0.01
Weighted average common shares outstanding - basic (in shares)	21,105,174	21,105,174
Add: Equivalent shares outstanding (in shares)	50,039	199,775
Shares issuable upon conversion of Convertible Debt - CD Financial, LLC (in shares)		8,230,769
Weighted average common shares outstanding - diluted (in shares)	21,155,213	29,535,718

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Current Assets:
Cash	$ 84	$ 71
Accounts receivable, net	2,803	2,638
Inventories	6,087	5,778
Investment in iBio, Inc.	501	501
Other current assets	358	334
Total current assets	9,833	9,322
Intangible assets, net	712	743
Property and equipment, net	1,368	1,373
Security deposits and other assets	164	185
Total Assets	12,077	11,623
Current Liabilities:
Advances under revolving credit facility	4,219	4,462
Accounts payable (includes $423 and $290 due to related party)	6,034	5,148
Accrued expenses and other current liabilities	1,189	1,536
Current portion of long term debt	707	719
Total current liabilities	12,149	11,865
Long term debt	3,830	3,942
Subordinated convertible note, net - CD Financial, LLC	5,148	5,120
Derivative liabilities	15	12
Total liabilities	$ 21,142	$ 20,939
Commitments and Contingencies
Stockholders' Deficiency:
Common Stock, $0.002 par value; 50,000,000 shares authorized; 21,140,074 and 21,105,174 shares issued and outstanding, respectively	$ 42	$ 42
Additional paid-in capital	44,684	44,676
Accumulated deficit	(53,692)	(53,935)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Deficiency	(9,065)	(9,316)
Total Liabilities and Stockholders' Deficiency	$ 12,077	$ 11,623

Condensed Consolidated Balance4

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Due to related party, current	$ 423	$ 290
Common stock, par value (in dollars per share)	$ 0.002	$ 0.002
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	21,140,074	21,140,074
Common stock, shares outstanding (in shares)	21,105,174	21,105,174
Treasury stock, shares outstanding (in shares)	34,900	34,900

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows provided by operating activities:
Net income	$ 241	$ 403
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization	91	95
Accretion of financing instruments and other non cash interest	60	$ 60
Stock based compensation	9
Change in fair value of derivative liabilities	3	$ (214)
Changes in operating assets and liabilities:
Accounts receivable	(165)	(119)
Inventories	(309)	(1,276)
Other current assets	(23)	(83)
Security deposits and other assets	(11)	(15)
Accounts payable	887	763
Accrued expenses and other liabilities	(347)	(109)
Net cash provided by (used in) operating activities	436	(495)
Cash flows from investing activities:
Purchase of property and equipment	(41)	(168)
Net cash used in investing activities	(41)	(168)
Cash flows from financing activities:
Advances under revolving credit facility	8,553	8,792
Proceeds from Line of Credit Note	43	205
Repayments of advances under revolving credit facility	(8,796)	(8,332)
Repayments under term note payables	(147)	(135)
Repayments under capitalized lease obligations	(35)	(24)
Net cash (used in) provided by financing activities	(382)	506
Net increase (decrease) in cash	13	(157)
Cash at beginning of period	71	451
Cash at end of period	84	294
Supplemental disclosures of cash flow information:
Interest	$ 173	$ 174
Income taxes
Supplemental disclosures of non-cash transactions:
Accretion on embedded derivative feature of convertible note payable	$ 28	$ 28
Amortization of prepaid financing costs	32	32
Financing on capitalized lease obligations	$ 14	$ 185

Note 1 - Principles of Consolid

Note 1 - Principles of Consolidation and Basis of Presentation	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Principles of Consolidation and Basis of Presentation Basis of Presentation of Interim Financial Statements The accompanying condensed consolidated financial statements for the interim periods are unaudited and include the accounts of Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”). The interim condensed consolidated financial statements have been prepared in conformity with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and therefore do not include information or footnotes necessary for a complete presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States of America. However, all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the periods presented have been included. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015 (“Form 10-K”), as filed with the SEC. The June 30, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The results of operations for the three months ended September 30, 2015 are not necessarily indicative of the results for the full fiscal year ending June 30, 2016 or for any other period. Nature of Operations The Company is engaged primarily in manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States, Luxembourg and Canada. The Company was previously known as Integrated Health Technologies, Inc. and, prior to that, as Chem International, Inc. The Company was reincorporated in its current form in Delaware in 1995. The Company continues to do business as Chem International, Inc. with certain of its customers and certain vendors. The Company’s business segments include: (a) Contract Manufacturing operated by InB:Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers; (b) Branded Proprietary Products operated by AgroLabs, Inc. (“AgroLabs”), which distributes healthful nutritional products for sale through major mass market, grocery, drug and vitamin retailers, under the following brands: Naturally Noni, Coconut Water, Aloe Pure, Peaceful Sleep, Green Envy, ACAI Extra, ACAI Cleanse, Wheatgrass and other products which are being introduced into the market (these are referred to as our branded proprietary nutraceutical business and/or products); and (c) Other Nutraceutical Businesses which includes the operations of (i) The Vitamin Factory (the “Vitamin Factory”), which sells private label MDC products, as well as our AgroLabs products, through the Internet, (ii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement and (iii) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. Significant Accounting Policies There have been no material changes during fiscal year 2016 in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015. Investment in iBio, Inc . Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014: Three Months Ended September 30, 2015 2014 Anti-dilutive stock options 1,080,950 401,200 Anti-dilutive shares for convertible notes payable 8,230,769 - Total anti-dilutive shares 9,311,719 401,200

Note 2 - Inventories

Note 2 - Inventories	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 2 . Inventories Inventories are stated at the lower of cost or market using the first-in, first-out method and consist of the following: September 30, June 30, 2015 2015 Raw materials $ 3,702 $ 2,371 Work-in-process 1,036 2,061 Finished goods 1,349 1,346 Total $ 6,087 $ 5,778

Note 3 - Intangible Assets, Net

Note 3 - Intangible Assets, Net	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 3. Intangible Assets, net Intangible assets consist of trade names, license fees from the Branded Proprietary Products Segment, and unpatented technology from the Other Nutraceutical Businesses Segment. The carrying amount of intangible assets, net is as follows as of: September 30, 2015 June 30, 2015 Gross Carrying Accumulated Gross Carrying Accumulated Amount Amortization Net Amount Amortization Net Trade names $ 1,525 $ 909 $ 616 $ 1,525 $ 891 $ 634 Unpatented technology 547 547 - 547 540 7 License agreement 347 251 96 347 245 102 Total $ 2,419 $ 1,707 $ 712 $ 2,419 $ 1,676 $ 743 Amortization expense recorded on intangible assets for the three months ended September 30, 2015 and 2014 was $31 and $34, respectively. Amortization expense is recorded on the straight-line method over periods ranging from 13 years to 20 years based on contractual or estimated lives and is included in selling and administrative expenses. Tests for impairment or recoverability are performed at least annually and require significant management judgment and the use of estimates which the Company believes are reasonable and appropriate at the time of the impairment test. Future unanticipated events affecting cash flows and changes in market conditions could affect such estimates and result in the need for an impairment charge. The Company also re-evaluates the periods of amortization to determine whether circumstances warrant revised estimates of current useful lives. No impairment losses were identified or recorded in the three months ended September 30, 2015 and 2014 on the Company’s intangible assets. The estimated annual amortization expense for intangible assets for the five succeeding fiscal years is as follows: Year ending Amortization June 30, Expense 2016, remaining $ 73 2017 97 2018 97 2019 97 2020 93 2021 76 Thereafter 179 Total $ 712

Note 4 - Property and Equipment

Note 4 - Property and Equipment	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4 . Property and Equipment, net Property and equipment, net consists of the following: September 30, June 30, 2015 2015 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,159 1,159 Machinery and equipment 5,416 5,362 Transportation equipment 16 16 7,841 7,787 Less: Accumulated depreciation and amortization (6,473 ) (6,414 ) Total $ 1,368 $ 1,373 Depreciation and amortization expense recorded on property and equipment for the three months ended September 30, 2015 and 2014 was $59 and $61, respectively.

Note 5 - Senior Credit Facility

Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 . Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt As of September 30, 2015 and June 30, 2015, the Company had the following debt outstanding: Principal Amount Interest Rate Maturity Date As of September 30, 2015 As of June 30, 2015 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 4,219 $ 4,462 3.25% 6/27/2017 Installment Note with PNC Bank 1,669 1,802 3.75% 6/27/2017 Line of Credit Note with PNC Equipment Finance 337 307 4.57% 7/29/2019 Promissory Note with CD Financial, LLC 1,714 1,714 6.00% 7/7/2017 Promissory Note with Vitamin Realty, LLC 686 686 4.00% 7/7/2017 Capitalized lease obligations 104 125 0.00% - 7.10% 2/26/2016 - 9/21/2017 Promissory Note with E. Gerald Kay 27 27 4.00% 7/7/2017 Total outstanding debt 8,756 9,123 Less: Revolving Advances (4,219 ) (4,462 ) Current portion of long term debt (707 ) (719 ) Long term debt $ 3,830 $ 3,942 Convertible Note payable - CD Financial, LLC $ 5,350 $ 5,350 6.00% 7/7/2017 Discount for embedded derivative (202 ) (230 ) Convertible Note payable, net - CD Financial, LLC $ 5,148 $ 5,120 SENIOR CREDIT FACILITY On June 27, 2012, the Company, MDC, AgroLabs, IHT, IHT Properties Corp. (“IHT Properties”) and Vitamin Factory (collectively, the “Borrowers”) entered into a Revolving Credit, Term Loan and Security Agreement (the “Loan Agreement”) with PNC Bank, National Association as agent and lender (“PNC”) and the other lenders party thereto. The Loan Agreement provides for a total of $11,727 in senior secured financing (the “Senior Credit Facility”) as follows: (i) discretionary advances (“Revolving Advances”) based on eligible accounts receivable and eligible inventory in the maximum amount of $8,000 (the “Revolving Credit Facility”) and (ii) a term loan in the amount of $3,727 (the “Term Loan”). The Senior Credit Facility is secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and common stock of iBio owned by the Company. Revolving Advances bear interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 2.75% (3.25% as of September 30, 2015 and June 30, 2015). The Term Loan bears interest at PNC’s Base Rate or the Eurodollar Rate, at Borrowers’ option, plus 3.25% (3.75% as of September 30, 2015 and June 30, 2015). Upon and after the occurrence of any event of default under the Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on June 27, 2017 (the “Senior Maturity Date”). The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Term Loan shall be repaid in sixty (60) consecutive monthly installments of principal, the first fifty nine (59) of which shall be in the amount of $44, commencing on the first business day of August, 2012, and continuing on the first business day of each month thereafter, with a final payment of any unpaid balance of principal and interest payable on the first business day of July, 2017. The foregoing is subject to customary mandatory prepayment provisions and acceleration upon the occurrence of any event of default under the Loan Agreement or earlier termination of the Loan Agreement pursuant to the terms thereof. The Revolving Advances are subject to the terms and conditions set forth in the Loan Agreement and are made in aggregate amounts at any time equal to the lesser of (x) $8.0 million or (y) an amount equal to the sum of: (i) up to 85%, subject to the provisions in the Loan Agreement, of eligible accounts receivables (“Receivables Advance Rate”), plus (ii) up to the lesser of (A) 65%, subject to the provisions in the Loan Agreement, of the value of the eligible inventory (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), (B) 85% of the appraised net orderly liquidation value of eligible inventory (as evidenced by the most recent inventory appraisal reasonably satisfactory to PNC in its sole discretion exercised in good faith) and (C) the inventory sublimit in the aggregate at any one time (“Inventory Advance Rate” and together with the Receivables Advance Rate, collectively, the “Advance Rates”), minus (iii) the aggregate Maximum Undrawn Amount of all outstanding Letters of Credit, minus (iv) such reserves as Agent may reasonably deem proper and necessary from time to time. The Loan Agreement contains customary mandatory prepayment provisions, including, without limitation, (i) the requirement that if the trading price per share of the iBio Stock falls below a certain amount, the Company must sell the iBio Stock and use the proceeds to repay the Term Loan and (ii) the requirement to prepay the outstanding amount of all loans in an amount equal to fifty percent (50%) of Excess Cash Flow for each fiscal year commencing with the fiscal year ending June 30, 2013, payable upon delivery of the financial statements to PNC referred to in and required by the Loan Agreement for such fiscal year but in any event not later than one hundred twenty (120) days after the end of each such fiscal year, which prepayment amount shall be applied ratably to the outstanding principal installments of the Term Loan in the inverse order of the maturities thereof until the aggregate amount of payments made with regard to the Term Loan pursuant to the Loan Agreement equals $1.0 million. The Loan Agreement also contains customary representations and warranties, covenants and events of default, including, without limitation, (i) a fixed charge coverage ratio maintenance requirement and (ii) an event of default tied to any change of control as defined in the Loan Agreement. As of September 30, 2015, the Company is in compliance with the fixed charge coverage ratio maintenance requirement. During certain periods in the fiscal year ended June 30, 2013 and continuing through the quarter ended September 30, 2015, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. However, PNC temporarily waived the requirement to sell the iBio Stock due to certain trading rules and restrictions under Rule 144 under the Securities Act of 1933, as amended. As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock, providing net trading proceeds of approximately $79 which proceeds were used to prepay principal outstanding under the Term Loan. In connection with the Senior Credit Facility, PNC and CD Financial entered into the Intercreditor and Subordination Agreement (the “Intercreditor Agreement”), which was acknowledged by the Borrowers, pursuant to which, among other things, (a) the lien of CD Financial on assets of the Borrowers is subordinated to the lien of PNC on such assets during the effectiveness of the Senior Credit Facility, and (b) priorities for payment of the debt for the Company and its subsidiaries (as described in this Note 5) are established. In addition, in connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC. CD FINANCIAL, LLC TROUBLED DEBT RESTRUCTURING On June 27, 2012, the Company also entered into an Amended and Restated Securities Purchase Agreement (the “CD SPA”) with CD Financial, which amended and restated the Securities Purchase Agreement, dated as of February 21, 2008, between the Company and CD Financial, pursuant to which the Company issued to CD Financial a 9.5% Convertible Senior Secured Note in the original principal amount of $4,500 (the “Original CD Note”). Pursuant to the CD SPA, the Company issued to CD Financial (i) the Amended and Restated Convertible Promissory Note in the principal amount of $5,350 (the “CD Convertible Note”) and (ii) the Promissory Note in the principal amount of $1,714 (the “Liquidity Note”, and collectively with the CD Convertible Note, the “CD Notes”). The CD Notes mature on July 7, 2017. The proceeds of the CD Notes were used to refinance (a) the Original CD Note, (b) a $300,000 note issued by MDC to CD Financial which was assigned by MDC to the Company, (c) past due interest in the aggregate amount of $333 and (d) other expenses owed to CD Financial by the Company in the aggregate amount of approximately $217. The CD Notes are secured by all assets of the Borrowers, including, without limitation, machinery and equipment, real estate owned by IHT Properties, and iBio Stock owned by the Company. The CD Notes bear interest at an annual rate of 6% and have a default rate of 10%. The CD Convertible Note is convertible at the option of CD Financial into common stock of the Company at a conversion price of $0.65 per share, subject to customary adjustments including conversion price protection provisions. Pursuant to the terms of the Loan Agreement and the Intercreditor Agreement, during the effectiveness of the Senior Credit Facility, (i) the principal of the CD Convertible Note may not be repaid, (ii) the principal of the Liquidity Note may only be repaid if certain conditions under the Loan Agreement are satisfied, and (iii) interest in respect of the CD Notes may only be paid if certain conditions under the Intercreditor Agreement are satisfied. The CD SPA contains customary representations and warranties, covenants and events of default, including, without limitation, an event of default tied to any change of control as defined in the CD SPA. In connection with the CD SPA, the Borrowers entered into an Amended and Restated Security Agreement and Amended and Restated Subsidiary Guaranty. As of September 30, 2015 and June 30, 2015, the related embedded derivative liability with respect to conversion price protection provisions on the CD Convertible Note has an estimated fair value of $15 and $12, respectively. The Company used the following assumptions to calculate the fair value of the derivative liability using the Black-Scholes option pricing model: September 30, June 30, June 27, 2015 2015 2012 Risk Free Interest Rate 0.64 % 0.64 % 0.72 % Volatility 70.80 % 71.60 % 144.10 % Term (years) 1.75 2 5 Dividend Rate 0.00 % 0.00 % 0.00 % Closing Price of Common Stock $ 0.10 $ 0.09 $ 0.09 OTHER LONG TERM DEBT Related Party Debt . Capitalized Lease Obligations. Equipment Financing Note. In addition, in connection with the LC Note, the following loan documents were executed: (i) a Security Agreement with PNCEF and MDC; (ii) a Guaranty and Security Agreement with PNCEF and the Company; and (iii) a Cross Collateralization Agreement with PNC, PNCEF and MDC.

Note 6 - Significant Risks and

Note 6 - Significant Risks and Uncertainties	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 6. Significant Risks and Uncertainties (a) Major Customers. (b) Other Business Risks.

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 7. Commitments and Contingencies (a) Leases Related Party Leases. Rent expense for the three months ended September 30, 2015 and 2014 on these leases were $184 and $210 respectively, and are included in both cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. As of September 30, 2015 and June 30, 2015, the Company had an outstanding obligation to Vitamin Realty of $1.2 million and $1.0 million, respectively, included in accounts payable, accrued expenses and other liabilities and long term debt in the accompanying Condensed Consolidated Balance Sheet. Other Lease Commitments. The minimum rental commitments for long-term non-cancelable leases are as follows: Operating Related Party Year ending Lease Lease June 30, Commitment Commitment Total 2016, remaining $ 40 $ 422 $ 462 2017 24 563 587 2018 14 563 577 2019 2 563 565 2020 1 563 564 2021 - 563 563 Thereafter - 2,517 2,517 Total $ 81 $ 5,754 $ 5,835 Total rent expense, including real estate taxes and maintenance charges, was approximately $225 and $252 for the three months ended September 30, 2015 and 2014, respectively. Rent expense is included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. (b) Legal Proceedings. The Company is subject, from time to time, to claims by third parties under various legal theories. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. (c) Other Claims. On May 15, 2012, Cedarburg Pharmaceuticals, Inc. ("Cedarburg") sent the Company a letter (the "Demand Letter") setting forth a demand for indemnification under the Stock Purchase Agreement, dated March 17, 2009 (the "Cedarburg SPA"), by and among Cedarburg, InB: Hauser Pharmaceutical Services, Inc., InB: Paxis Pharmaceuticals, Inc. and the Company. In the Demand Letter, Cedarburg demanded payment by the Company of $0.6 million in respect of the Company's indemnification obligations under the Cedarburg SPA. In addition, in the Demand Letter, Cedarburg informed the Company that there are also environmental issues pending which may lead to additional costs to Cedarburg which will likely be in excess of $0.3 million. On May 30, 2012, the Company sent a letter responding to the Demand Letter and setting forth the Company’s position that it has no obligation to indemnify Cedarburg as demanded. On June 18, 2012, Cedarburg responded to the Company’s letter and, on July 27, 2012, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. On December 18, 2012, Cedarburg responded to the Company’s letter and, on January 15, 2013, the Company sent another letter to Cedarburg reiterating its position that the Company has no obligation to indemnify Cedarburg as demanded. As of November 5, 2015, the Company has not received any further communication from Cedarburg with respect to its demand for indemnification as set forth in the Demand Letter. The Company intends to vigorously contest Cedarburg's demand as set forth in the Demand Letter.

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 8. Related Party Transactions See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt for related party securities transactions. See Note 7(a). Leases for related party lease transactions.

Note 9 - Segment Information

Note 9 - Segment Information	3 Months Ended
	Sep. 30, 2015
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 9. Segment Information The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments. The Company has divided its operations into three reportable segments as follows: Contract Manufacturing, Branded Proprietary Products and Other Nutraceutical Businesses. The international sales, concentrated primarily in Europe and Canada, for the three months ended September 30, 2015 and 2014 were $1,992 and $2,283, respectively. Financial information relating to the three months ended September 30, 2015 and 2014 operations by business segment are as follows: Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit Depreciation Expenditures Contract Manufacturing 2015 $ 6,930 $ 1,815 $ 8,745 $ 1,041 $ 59 $ 54 2014 5,743 2,065 7,808 1,151 60 351 Branded Proprietary Products 2015 147 172 319 128 - - 2014 129 210 339 6 - 1 Other Nutraceutical Businesses 2015 376 5 381 146 - 1 2014 427 8 435 144 1 - Total Company 2015 7,453 1,992 9,445 1,315 59 55 2014 6,299 2,283 8,582 1,301 61 352 Total Assets as of September 30, June 30, 2015 2015 Contract Manufacturing $ 9,113 $ 8,482 Branded Proprietary Products 1,296 1,324 Other Nutraceutical Businesses 1,668 1,817 Total Company $ 12,077 $ 11,623

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Equity Method Investments, Policy [Policy Text Block]	Investment in iBio, Inc . Pursuant to the Company’s Loan Agreement with PNC Bank, National Association (“PNC”), the Company is required to sell the iBio Stock when the trading price of the iBio Stock is less than $0.88 per share for a period of fifteen (15) consecutive trading days on the applicable exchange and utilize all proceeds from such sale to prepay the outstanding principal of the term loan outstanding under the Loan Agreement at such time. During certain periods in the three months ended September 30, 2015 and the fiscal years ended June 30, 2015, 2014 and 2013, the trading price of the iBio Stock was less than $0.88 for a period of fifteen (15) consecutive trading days. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt). As of November 5, 2015, PNC has not required the Company to sell any of the iBio Stock but reserves the right to do so at any time in the future. Although not required to do so, in the quarter ended June 30, 2015, the Company sold 73,191 shares of iBio Stock providing net trading proceeds of approximately $79 which were used to prepay principal outstanding under the Term Loan. (See Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt).
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share. The following options and potentially dilutive shares for convertible notes payable (see Note 5. Senior Credit Facility, Subordinated Convertible Note, net - CD Financial, LLC and other Long Term Debt) were not included in the computation of weighted average diluted common shares outstanding as the effect of doing so would be anti-dilutive for the three months ended September 30, 2015 and 2014: Three Months Ended September 30, 2015 2014 Anti-dilutive stock options 1,080,950 401,200 Anti-dilutive shares for convertible notes payable 8,230,769 - Total anti-dilutive shares 9,311,719 401,200

Note 1 - Principles of Consol16

Note 1 - Principles of Consolidation and Basis of Presentation (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, 2015 2014 Anti-dilutive stock options 1,080,950 401,200 Anti-dilutive shares for convertible notes payable 8,230,769 - Total anti-dilutive shares 9,311,719 401,200

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, June 30, 2015 2015 Raw materials $ 3,702 $ 2,371 Work-in-process 1,036 2,061 Finished goods 1,349 1,346 Total $ 6,087 $ 5,778

Note 3 - Intangible Assets, N18

Note 3 - Intangible Assets, Net (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2015 June 30, 2015 Gross Carrying Accumulated Gross Carrying Accumulated Amount Amortization Net Amount Amortization Net Trade names $ 1,525 $ 909 $ 616 $ 1,525 $ 891 $ 634 Unpatented technology 547 547 - 547 540 7 License agreement 347 251 96 347 245 102 Total $ 2,419 $ 1,707 $ 712 $ 2,419 $ 1,676 $ 743
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending Amortization June 30, Expense 2016, remaining $ 73 2017 97 2018 97 2019 97 2020 93 2021 76 Thereafter 179 Total $ 712

Note 4 - Property and Equipme19

Note 4 - Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, June 30, 2015 2015 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,159 1,159 Machinery and equipment 5,416 5,362 Transportation equipment 16 16 7,841 7,787 Less: Accumulated depreciation and amortization (6,473 ) (6,414 ) Total $ 1,368 $ 1,373

Note 5 - Senior Credit Facili20

Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Debt [Table Text Block]	Principal Amount Interest Rate Maturity Date As of September 30, 2015 As of June 30, 2015 Revolving advances under Senior Credit Facility with PNC Bank, National Association $ 4,219 $ 4,462 3.25% 6/27/2017 Installment Note with PNC Bank 1,669 1,802 3.75% 6/27/2017 Line of Credit Note with PNC Equipment Finance 337 307 4.57% 7/29/2019 Promissory Note with CD Financial, LLC 1,714 1,714 6.00% 7/7/2017 Promissory Note with Vitamin Realty, LLC 686 686 4.00% 7/7/2017 Capitalized lease obligations 104 125 0.00% - 7.10% 2/26/2016 - 9/21/2017 Promissory Note with E. Gerald Kay 27 27 4.00% 7/7/2017 Total outstanding debt 8,756 9,123 Less: Revolving Advances (4,219 ) (4,462 ) Current portion of long term debt (707 ) (719 ) Long term debt $ 3,830 $ 3,942 Convertible Note payable - CD Financial, LLC $ 5,350 $ 5,350 6.00% 7/7/2017 Discount for embedded derivative (202 ) (230 ) Convertible Note payable, net - CD Financial, LLC $ 5,148 $ 5,120
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	September 30, June 30, June 27, 2015 2015 2012 Risk Free Interest Rate 0.64 % 0.64 % 0.72 % Volatility 70.80 % 71.60 % 144.10 % Term (years) 1.75 2 5 Dividend Rate 0.00 % 0.00 % 0.00 % Closing Price of Common Stock $ 0.10 $ 0.09 $ 0.09

Note 7 - Commitments and Cont21

Note 7 - Commitments and Contingencies (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Operating Related Party Year ending Lease Lease June 30, Commitment Commitment Total 2016, remaining $ 40 $ 422 $ 462 2017 24 563 587 2018 14 563 577 2019 2 563 565 2020 1 563 564 2021 - 563 563 Thereafter - 2,517 2,517 Total $ 81 $ 5,754 $ 5,835

Note 9 - Segment Information (T

Note 9 - Segment Information (Tables)	3 Months Ended
	Sep. 30, 2015
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales, Net Segment U.S. International Gross Capital Customers Customers Total Profit Depreciation Expenditures Contract Manufacturing 2015 $ 6,930 $ 1,815 $ 8,745 $ 1,041 $ 59 $ 54 2014 5,743 2,065 7,808 1,151 60 351 Branded Proprietary Products 2015 147 172 319 128 - - 2014 129 210 339 6 - 1 Other Nutraceutical Businesses 2015 376 5 381 146 - 1 2014 427 8 435 144 1 - Total Company 2015 7,453 1,992 9,445 1,315 59 55 2014 6,299 2,283 8,582 1,301 61 352
Reconciliation of Assets from Segment to Consolidated [Table Text Block]	Total Assets as of September 30, June 30, 2015 2015 Contract Manufacturing $ 9,113 $ 8,482 Branded Proprietary Products 1,296 1,324 Other Nutraceutical Businesses 1,668 1,817 Total Company $ 12,077 $ 11,623

Note 1 - Principles of Consol23

Note 1 - Principles of Consolidation and Basis of Presentation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	86 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Jun. 27, 2012
Minimum [Member] | IBio Inc [Member]
Share Price	$ 0.88	$ 0.88	$ 0.88	$ 0.88	$ 0.88
IBio Inc [Member] | Minimum Share Price Acceptable Before Required to Sell [Member]
Share Price	$ 0.88	$ 0.88
IBio Inc [Member]
Equity Method Investment, Ownership Percentage	6.00%	6.00%
Investment Owned, Balance, Shares	1,266,706	1,266,706
Asset Impairment Charges		$ 2,200
Investment Owned, at Fair Value	$ 800	$ 800
Consecutive Trading Days for Stock Price Threshold	15 days
Investment, Shares Sold	73,191
Proceeds from Sale of Long-term Investments	$ 79
Share Price	$ 0.10	$ 0.10	$ 0.09			$ 0.09

Note 1 - Antidilutive Securitie

Note 1 - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Employee Stock Option [Member]
Anti-dilutive stock options (in shares)	1,080,950	401,200
Warrant [Member]
Anti-dilutive stock options (in shares)	8,230,769
Anti-dilutive stock options (in shares)	9,311,719	401,200

Note 2 - Inventories - Inventor

Note 2 - Inventories - Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Raw materials	$ 3,702	$ 2,371
Work-in-process	1,036	2,061
Finished goods	1,349	1,346
Total	$ 6,087	$ 5,778

Note 3 - Intangible Assets, N26

Note 3 - Intangible Assets, Net (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	13 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	20 years
Impairment of Intangible Assets, Finite-lived	$ 0	$ 0
Amortization of Intangible Assets	$ 31,000	$ 34,000

Note 3 - Intangible Assets, N27

Note 3 - Intangible Assets, Net - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Trade Names [Member]
Gross Carrying Amount	$ 1,525	$ 1,525
Accumulated Amortization	909	891
Net	616	634
Unpatented Technology [Member]
Gross Carrying Amount	547	547
Accumulated Amortization	$ 547	540
Net		7
Licensing Agreements [Member]
Gross Carrying Amount	$ 347	347
Accumulated Amortization	251	245
Net	96	102
Gross Carrying Amount	2,419	2,419
Accumulated Amortization	1,707	1,676
Net	$ 712	$ 743

Note 3 - Intangible Assets, N28

Note 3 - Intangible Assets, Net - Estimated Annual Amortization Expense for Intangible Assets (Details) $ in Thousands	Sep. 30, 2015USD ($)
2016, remaining	$ 73
2,017	97
2,018	97
2,019	97
2,020	93
2,021	76
Thereafter	179
Total	$ 712

Note 4 - Property and Equipme29

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Depreciation	$ 59	$ 61

Note 4 - Property and Equipme30

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2014
Land and Building [Member]
Property and equipment, gross	$ 1,250	$ 1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,159	1,159
Machinery and Equipment [Member]
Property and equipment, gross	5,416	5,362
Transportation Equipment [Member]
Property and equipment, gross	16	16
Property and equipment, gross	7,841	7,787
Less: Accumulated depreciation and amortization	(6,473)	(6,414)
Total	$ 1,368	$ 1,373

Note 5 - Senior Credit Facili31

Note 5 - Senior Credit Facility, Subordinated Convertible Note Payable, Net - CD Financial, LLC and Other Long-Term Debt (Details Textual) - USD ($)	Sep. 17, 2015	Jul. 29, 2015	Jun. 27, 2012	Sep. 22, 2014	Jun. 27, 2012	Sep. 30, 2015	Sep. 30, 2014	Nov. 05, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013	Feb. 21, 2008
Eurodollar [Member] | Term Loan [Member]
Line of Credit Facility, Interest Rate at Period End						3.75%			3.75%
Debt Instrument, Basis Spread on Variable Rate						3.25%
Eurodollar [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Interest Rate at Period End						3.25%			3.25%
Debt Instrument, Basis Spread on Variable Rate						2.75%
Term Loan [Member] | Scenario Event of Default [Member]
Number of Consecutive Monthly Installments						60
Number of Consecutive Monthly Installments, Fixed Amount						59
Debt Instrument, Interest Rate, Increase (Decrease)						2.00%
Revolving Advances [Member]
Line of Credit Facility Covenant Aggregate Revolving Advance Percentage of Appraised Net Orderly Liquidation Value of Eligible Inventory						85.00%
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance						$ 8,000,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate						85.00%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate						65.00%
Loan Agreement Mandatory Repayment Amount						$ 1,000,000
Loan Agreement [Member]
Line of Credit Facility Covenant Prepayment Provisions Percentage of Excess Cash flow											50.00%
Promissory Note [Member] | CD Financial LLC [Member]
Debt Instrument, Face Amount			$ 1,714,000		$ 1,714,000
CD MDC Note [Member]
Repayments of Notes Payable			300,000
E. Gerald Kay [Member] | Vitamin Realty LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage						4.00%
Term Note [Member] | Convertible Line of Credit Note [Member] | Subsequent Event [Member]
Debt Instrument, Term		4 years
Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate		4.57%
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 8,000,000		$ 8,000,000
Convertible Line of Credit Note [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 350,000
Debt Instrument, Basis Spread on Variable Rate				3.25%
Debt Instrument Convertible Aggregate Amount Advanced Trigger				$ 350,000
Long-term Line of Credit						$ 350,000
IBio Inc [Member] | Minimum [Member]
Share Price						$ 0.88			$ 0.88	$ 0.88	$ 0.88
IBio Inc [Member]
Consecutive Trading Days for Stock Price Threshold						15 days
Investment, Shares Sold						73,191
Proceeds from Sale of Long-term Investments						$ 79,000
Subsequent Event [Member] | Regents [Member]
Borrowings to Finance Machinery and Equipment to Secure Capital Lease								$ 14,000
Regents [Member]
Borrowings to Finance Machinery and Equipment to Secure Capital Lease						14,000
Debt Instrument, Interest Rate, Stated Percentage	5.70%
Capital Lease Obligations	$ 90,000
Capital Lease Obligation Quarterly Lease Payment	$ 2,000
CD Financial LLC [Member] | Default Rate [Member]
Debt Instrument, Interest Rate, Stated Percentage			10.00%		10.00%
CD Financial LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage			6.00%		6.00%							9.50%
Debt Instrument, Face Amount												$ 4,500,000
Convertible Notes Payable			$ 5,350,000		$ 5,350,000
Debt Instrument, Convertible, Conversion Price			$ 0.65		$ 0.65
Embedded Derivative, Fair Value of Embedded Derivative Liability						15,000			$ 12,000
Vitamin Realty LLC [Member]
Debt Instrument, Face Amount						686,000
E. Gerald Kay [Member]
Debt Instrument, Face Amount						27,000
Senior Notes			$ 11,727,000		$ 11,727,000
Loans Payable, Noncurrent			$ 3,727,000		$ 3,727,000
Debt Instrument, Periodic Payment						$ 44,000
Share Price			$ 0.09		$ 0.09	$ 0.10			$ 0.09
Repayments of Notes Payable						$ 147,000	$ 135,000
Interest Paid					$ 333,000	173,000	$ 174,000
Other Expenses					$ 217,000
Capital Lease Obligations						$ 104,000			$ 125,000

Note 5 - Senior Credit Facili32

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Debt Outstanding (Details) - USD ($)	3 Months Ended
	Sep. 30, 2015	Jun. 30, 2015
PNC Bank [Member] | Revolving Credit Facility [Member]
Line of Credit Facility	$ 4,219	$ 4,462
Line of Credit Facility, Interest Rate at Period End	3.25%
Maturity date	Jun. 27, 2017
Less: Revolving Advances	$ (4,219)	(4,462)
PNC Bank [Member]
Maturity date	Jun. 27, 2017
Notes Payable	$ 1,669,000	1,802,000
Interest rate	3.75%
PNC Equipment Finance Llc [Member]
Line of Credit Facility	$ 337	307
Line of Credit Facility, Interest Rate at Period End	4.57%
Maturity date	Jul. 29, 2019
Less: Revolving Advances	$ (337)	(307)
CD Financial LLC [Member]
Maturity date	Jul. 7, 2017
Notes Payable	$ 1,714,000	1,714,000
Interest rate	6.00%
Vitamin Realty LLC [Member]
Maturity date	Jul. 7, 2017
Notes Payable	$ 686,000	686,000
Interest rate	4.00%
E. Gerald Kay [Member]
Maturity date	Jul. 7, 2017
Notes Payable	$ 27,000	27,000
Interest rate	4.00%
Minimum [Member]
Capitalized lease obligations	0.00%
Capitalized lease obligations	Feb. 26, 2016
Maximum [Member]
Capitalized lease obligations	7.10%
Capitalized lease obligations	Sep. 21, 2017
Convertible Debt [Member]
Maturity date	Jul. 7, 2017
Notes Payable	$ 5,350,000	5,350,000
Interest rate	6.00%
Line of Credit Facility	$ 4,219,000	4,462,000
Capital Lease Obligations	104,000	125,000
Total outstanding debt	8,756,000	9,123,000
Less: Revolving Advances	(4,219,000)	(4,462,000)
Current portion of long term debt	(707,000)	(719,000)
Long term debt	3,830,000	3,942,000
Discount for embedded derivative	(202,000)	(230,000)
Convertible Note payable, net - CD Financial, LLC	$ 5,148,000	$ 5,120,000

Note 5 - Senior Credit Facili33

Note 5 - Senior Credit Facility, Subordinated Convertible Note, Net - CD Financial, LLC and other Long Term Debt - Calculation of Fair Value of Derivative Liability (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Jun. 27, 2012
Derivative [Member]
Risk Free Interest Rate	0.64%	0.64%	0.72%
Volatility	70.80%	71.60%	144.10%
Term (years)	1 year 273 days	2 years	5 years
Dividend Rate	0.00%	0.00%	0.00%
Common Stock (in dollars per share)	$ 0.10	$ 0.09	$ 0.09

Note 6 - Significant Risks an34

Note 6 - Significant Risks and Uncertainties (Details Textual)	3 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015
Sales Revenue, Net [Member] | Major Customer 1 [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	47.00%	47.00%
Sales Revenue, Net [Member] | Two Customers [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	87.00%	81.00%
Sales Revenue, Net [Member] | Major Customer 2 [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	63.00%	26.00%
Sales Revenue, Net [Member] | Major Customer 3 [Member] | Customer Concentration Risk [Member] | Branded Proprietary Products [Member]
Concentration Risk, Percentage	77.00%	78.00%
Accounts Receivable [Member] | Three Customers [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	86.00%		83.00%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage	62.00%

Note 7 - Commitments and Cont35

Note 7 - Commitments and Contingencies (Details Textual)	3 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)	May. 19, 2014ft²	May. 15, 2012USD ($)	Jan. 05, 2012ft²	Jan. 04, 2012ft²
Manhattan Drug Company [Member]
Area of Real Estate Property | ft²						76,161	74,898
Payments for Rent	$ 533,000
AgroLabs [Member]
Area of Real Estate Property | ft²				2,700
Payments for Rent	27,000
Vitamin Realty LLC [Member]
Operating Leases, Rent Expense	184,000	$ 210,000
Accrued Rent	1,200,000		$ 1,000,000
Stock Purchase Agreement [Member]
Loss Contingency, Estimate of Possible Loss					$ 600,000
Environmental Issues [Member]
Loss Contingency, Estimate of Possible Loss					$ 0.30
Operating Leases, Rent Expense	$ 225	$ 252

Note 7 - Minimum Rental Commitm

Note 7 - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) $ in Thousands	Sep. 30, 2015USD ($)
Operating Lease Commitment [Member]
2016, remaining	$ 40
2,017	24
2,018	14
2,019	2
2,020	$ 1
2,021
Thereafter
Total	$ 81
Related Party Lease Commitment [Member]
2016, remaining	422
2,017	563
2,018	563
2,019	563
2,020	563
2,021	563
Thereafter	2,517
Total	5,754
2016, remaining	462
2,017	587
2,018	577
2,019	565
2,020	564
2,021	563
Thereafter	2,517
Total	$ 5,835

Note 9 - Segment Information (D

Note 9 - Segment Information (Details Textual) $ in Thousands	3 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Europe and Canada [Member]
Revenues	$ 1,992	$ 2,283
Number of Reportable Segments	3

Note 9 - Segment Information -

Note 9 - Segment Information - Operations by Business Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Contract Manufacturing [Member] | UNITED STATES
Sales, net	$ 6,930	$ 5,743
Contract Manufacturing [Member] | International Customers [Member]
Sales, net	1,815	2,065
Contract Manufacturing [Member]
Sales, net	8,745	7,808
Gross profit	1,041	1,151
Depreciation	59	60
Capital expenditures	54	351
Branded Proprietary Products [Member] | UNITED STATES
Sales, net	147	129
Branded Proprietary Products [Member] | International Customers [Member]
Sales, net	172	210
Branded Proprietary Products [Member]
Sales, net	319	339
Gross profit	$ 128	$ 6
Depreciation
Capital expenditures		$ 1
Other Nutraceutical Business [Member] | UNITED STATES
Sales, net	$ 376	427
Other Nutraceutical Business [Member] | International Customers [Member]
Sales, net	5	8
Other Nutraceutical Business [Member]
Sales, net	381	435
Gross profit	$ 146	144
Depreciation		$ 1
Capital expenditures	$ 1
UNITED STATES
Sales, net	7,453	$ 6,299
International Customers [Member]
Sales, net	1,992	2,283
Sales, net	9,445	8,582
Gross profit	1,315	1,301
Depreciation	59	61
Capital expenditures	$ 55	$ 352

Note 9 - Segment Information 39

Note 9 - Segment Information - Operations by Business Segment - Total Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Jun. 30, 2015
Contract Manufacturing [Member]
Total Assets	$ 9,113	$ 8,482
Branded Proprietary Products [Member]
Total Assets	1,668	1,817
Total Assets	$ 12,077	$ 11,623